COVAD survey 2 long-term outcomes: unmet need and protocol
Zoha Zahid Fazal,Parikshit Sen,Mrudula Joshi,Naveen Ravichandran,James B. Lilleker,Vishwesh Agarwal,Sinan Kardeş,Minchul Kim,Jessica Day,Ashima Makol,Marcin Milchert,Tamer A. Gheita,Babur Salim,Tsvetelina Velikova,Abraham Edgar Gracia-Ramos,Ioannis Parodis,Elena Nikiphorou,Ai Lyn Tan,T Chatterjee,Lorenzo Cavagna,Miguel A. Saavedra,Samuel Katsuyuki Shinjo,Nelly Ziade,Albert Selva-O'Callaghan,Arvind Nune,Johannes Knitza,Masataka Kuwana,C. Gutierrez,Carlo V. Caballero-Uribe,Dzifa Dey,Oliver Distler,Hector Chinoy,Vikas Agarwal,Rohit Aggarwal,Latika Gupta,Bhupen Barman,Yogesh P. Singh,Rajiv Ranjan,Avinash Jain,Sapan Pandya,Rakesh Kumar Pilania,Aman Sharma,Manawil M,Vikas Gupta,Chengappa Kavadichanda,Pradeepta Sekhar Patro,Sajal Ajmani,Sanat Phatak,Rama Prosad Goswami,Abhra Chandra Chowdhury,Ashish Mathew,Padnamabha Shenoy,Ajay Asranna,Keerthi Talari Bommakanti,Anuj Shukla,Arun K. Pandey,Prithvi Sanjeevkumar Gaur,Mahabaleshwar Sangappa Mamadapur,Akanksha Ghodke,Kunal Chandwar,Kshitij Jagtap,Döndü Üsküdar Cansu,R Yildirim,Aarat M. Patel,John D Pauling,Chris Wincup,Margherita Giannini,François Maurier,J. Van Lockeren Campagne,Alain Meyer,N. Del Papa,Gianluca Sambataro,Atzeni Fabiola,Marcello Govoni,Simone Parisi,Elena Bartoloni Bocci,Gian Domenico Sebastiani,Enrico Fusaro,Marco Sebastiani,Luca Quartuccio,Franco Franceschini,Pier Paolo Sainaghi,Giovanni Orsolini,R. De Angelis,Mary Danielli,Vincenzo Venerito,Silvia Grignaschi,Alessandro Giollo,L. Traboco,Syahrul Sazliyana Shaharir,Suryo Anggoro Kusumo Wibowo,Erick Adrian Zamora Tehozol,Jorge Rojas Serrano,Ignacio García-De La Torre,Iris Jazmin Colunga-Pedraza,Javier Merayo-Chalico,Jesús Loarce-Martos,Sergio Prieto-González,Albert Gil-Vila,Raquel Aranega,Leonardo Santos Hoff,Ran Nakashima,Shinji Sato,Naoki Kimura,Yuko Kaneko,Stylianos Tomaras,Fabian Proft,M. Holzer,M. A. Gromova,O Aharonov,Melinda Nagy-Vincze,Zoltán Griger,Ihsane Hmamouchi,Pr Imane El bouchti,Zineb Baba,U. Ima-Edomwonyi,Ibukunoluwa A Dedeke,Emorinken Airenakho,Nwankwo Henry Madu,Abubakar Yerima,Hakeem Olaosebikan,Okwara Celestine Chibuzo,Becky A,Ouma Devi Koussougbo,E. Palalane,Daman Langguth,Vidya Limaye,Merrilee Needham,Nilesh Srivastav,Marie Hudson,Océane Landon-Cardinal,W. G. Rojas Zuleta,A. Arbelaez,Javier Cajas,JOSÉ ANTÓNIO P. Silva,João Eurico Fonseca,Olena Zimba,Doskaliuk Bohdana,Ho So,Manuel F. Ugarte-Gil,Lyn Chinchay,José Proaño Bernaola,Víctor Pimentel,A. T. M. Tanveer Hasan,Sreoshy Saha,Binit Vaidya,Hanan M. Fathi,Reem Hamdy A Mohammed,Yi-Ming Chen,Ghita Harifi,Lina El Kibbi,Hussein Halabi,P Akawatcharangura,Wanruchada Katchamart,Yurilis J Fuentes-Silva,Karoll Cabriza,Jonathan Losanto,Nelly Colaman,Antonio Cachafeiro-Vilar,Generoso Guerra Bautista,Enrique Julio Giraldo Ho,Raúl Agustín González,Lilith Stange Nunez,Cristian Vergara M,Jossiell Then Báez,H. F. Navas Alonzo,C. S. Pastelín,Rodrigo Salinas,Alejandro Quiñónez Obiols,Nilmo Chávez,Andrea Ordonez,Sandra Argueta,Daniel Quijivix,Gil Alberto Reyes Llerena,Radamés Sierra-Zorita,Dina Arrieta,Eduardo Romero Hidalgo,Ricardo Saenz,Idania Escalante M.,Roberto Lavadenz Morales,Wendy Calapaqui,I. Quezada,Gabriela F. Arredondo +182 more
Reads0
Chats0
TLDR
The COVAD-2 survey as mentioned in this paper collected patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation, with the aim of collecting patientreported data to improve vaccination efforts.Abstract:
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups. read more
Citations
More filters
Journal ArticleDOI
COVID-19 vaccination in autoimmune diseases (COVAD) Study: vaccine safety and tolerance in rheumatoid arthritis.
N. R,Ioannis Parodis,Mrudula Joshi,Parikshit Sen,J. Lindblom,Vishwesh Agarwal,James B. Lilleker,Ai Lyn Tan,Arvind Nune,Samuel Katsuyuki Shinjo,Babur Salim,Nelly Ziade,Tsvetelina Velikova,Abraham Edgar Gracia-Ramos,Miguel A. Saavedra,J. Day,Ashima Makol,Oliver Distler,Hector Chinoy,Vikas Agarwal,Rohit Aggarwal,Latika Gupta,Elena Nikiphorou +22 more
TL;DR: The COVID-19 vaccination in autoimmune diseases (COVAD) study as discussed by the authors aimed to assess short-term COVID19 vaccination-related adverse events (AEs) in rheumatoid arthritis patients.
Journal ArticleDOI
Vaccine hesitancy decreases, long term concerns remain in myositis, rheumatic disease patients: A comparative analysis of the COVAD surveys.
Parikshit Sen,R Naveen,Nazanin Houshmand,Siamak Moghadam Kia,Mrudula Joshi,Sreoshy Saha,Kshitij Jagtap,Vishwesh Agarwal,Arvind Nune,Elena Nikiphorou,Ai Lyn Tan,Samuel Katsuyuki Shinjo,Nelly Ziade,Tsvetelina Velikova,Marcin Milchert,Ioannis Parodis,Abraham Edgar Gracia-Ramos,Lorenzo Cavagna,Masataka Kuwana,Johannes Knitza,Ashima Makol,Aarat M. Patel,John D Pauling,Chris Wincup,Bhupen Barman,Erick Adrian Zamora Tehozol,Jorge Rojas Serrano,Ignacio García-De La Torre,Iris Jazmin Colunga-Pedraza,Javier Merayo-Chalico,Okwara Celestine Chibuzo,Wanruchada Katchamart,Phonpen Akawatcharangura Goo,Russka Shumnalieva,Yi-Ming Chen,Leonardo Santos Hoff,Lina El Kibbi,Hussein Halabi,Binit Vaidya,Syahrul Sazliyana Shaharir,A. T. M. Tanveer Hasan,Dzifa Dey,C. Gutierrez,Carlo V. Caballero-Uribe,James B. Lilleker,Babur Salim,Tamer A. Gheita,T Chatterjee,Oliver Distler,Miguel A. Saavedra,J. Day,Hector Chinoy,Vikas Agarwal,Rohit Aggarwal,Latika Gupta +54 more
TL;DR: In this article , the authors studied the prevalence, predictors, and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys.
Journal ArticleDOI
COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies.
Laura Andreoli,Parikshit Sen,Daniele Lini,Melinda Vincze,Karen Schreiber,Vikas Agarwal,Rohit Aggarwal,Latika Gupta +7 more
TL;DR: In this paper , the COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies was evaluated in a study conducted at the University of Oxford.
Journal ArticleDOI
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
TL;DR: In this article , a negative binomial regression analysis was performed to assess pain in IIMs subtypes and whether demographics, disease activity, general health status, and physical function had an impact on pain scores.
Journal ArticleDOI
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
Samuel Katsuyuki Shinjo,Minchul Kim,Leonardo Santos Hoff,Rafael Giovani Misse,Parikshit Sen,R Naveen,Jessica Day,Rafael Alves Cordeiro,Jucier Gonçalves Júnior,T Chatterjee,James B. Lilleker,Vishwesh Agarwal,Sinan Kardeş,Marcin Milchert,Tamer A. Gheita,Babur Salim,Tsvetelina Velikova,Abraham Edgar Gracia-Ramos,Ioannis Parodis,Albert Selva-O'Callaghan,Elena Nikiphorou,Ashima Makol,Ai Lyn Tan,Lorenzo Cavagna,Miguel A. Saavedra,Nelly Ziade,Johannes Knitza,Masataka Kuwana,Arvind Nune,Oliver Distler,Hector Chinoy,Vikas Agarwal,Rohit Aggarwal,Latika Gupta +33 more
TL;DR: In this article , the authors compare pain intensity among individuals with idiopathic inflammatory myopathies (IIMs), other systemic autoimmune rheumatic diseases (AIRDs), and without Rheumatic disease (wAIDs).
References
More filters
Journal ArticleDOI
Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES)
TL;DR: A checklist of recommendations for authors is being presented by theJMIR in an effort to ensure complete descriptions of Web-based surveys and it is hoped that author adherence to the checklist will increase the usefulness of such reports.
Journal ArticleDOI
Vaccine hesitancy: Definition, scope and determinants.
TL;DR: The SAGE Working Group on Vaccine Hesitancy concluded that vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite availability of vaccination services.
Journal ArticleDOI
Covid-19 - Implications for the Health Care System.
TL;DR: The Covid-19 pandemic has exposed and exacerbated weaknesses in the U.S. health care system and many patients are losing their health insurance when the pandemic ends, research suggests.
Journal ArticleDOI
Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study.
Max Augustin,Philipp Schommers,Melanie Stecher,Felix Dewald,Lutz Gieselmann,Henning Gruell,Carola Horn,Kanika Vanshylla,Veronica Di Cristanziano,Luise Osebold,Maria Roventa,Toqeer Riaz,Nikolai Tschernoster,Janine Altmueller,Leonard Rose,Susanne Salomon,Vanessa Priesner,Jan Christoffer Luers,Christian Albus,Stephan Rosenkranz,Birgit S. Gathof,Gerd Fätkenheuer,Michael Hallek,Florian Klein,Isabelle Suárez,Clara Lehmann +25 more
TL;DR: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS).
Journal ArticleDOI
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis
Wen Wen,Chun-Yi Wang,Mengyun Zhou,Yongran Cheng,Xiang Zhao,Qi Wu,Xing-Wei Zhang,Zhan-Hui Feng,Ming-Wei Wang,Qin Mao +9 more
TL;DR: This study showed that three novel oral antivirals (molnupiravir, fluvoxamine and Paxlovid) are effective in reducing the mortality and hospitalization rates in patients with COVID-19.